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Abstract
In the past few decades, gout has increased not only in
prevalence, but also in clinical complexity, the latter accentuated in
part by a dearth of novel advances in treatments for hyperuricemia
and gouty arthritis. Fortunately, recent research reviewed here,
much of it founded on elegant translational studies of the past
decade, highlights how gout can be better managed with cost-
effective, well-established therapies. In addition, the advent of both
new urate-lowering and anti-inflammatory drugs, also reviewed
here, promises for improved management of refractory gout,
including in subjects with co-morbidities such as chronic kidney
disease. Effectively delivering improved management of hyper-
uricemia and gout will require a frame shift in practice patterns,
including increased recognition of the implications of refractory
disease and frequent noncompliance of patients with gout, and
understanding the evidence basis for therapeutic targets in serum
urate-lowering and gouty inflammation.
Introduction
In the past few decades in the USA and elsewhere, gout has
markedly increased in incidence and prevalence [1-3]. This
includes a marked increase in gout in patients over the age of
65, and even more so in patients over 75 years of age, in
lockstep with high prevalence of conditions linked with
hyperuricemia (chronic kidney disease (CKD), hypertension,
metabolic syndrome and diabetes, and congestive heart
failure) and rampant use of diuretics and low dose acetyl-
salicylic acid [1-3]. Gout patients in this day and age are
more clinically complex than in past memory, due to various
combinations of advanced age, co-morbidities, potential
drug-drug interactions, and refractory tophaceous disease
[1]. In this light, clinicians are increasingly faced with patients
with refractory gout, classic features of which are summarized
in Table 1. Until recently, a lack of an innovative pipeline of
emerging therapies for hyperuricemia and gouty inflammation
has compounded this situation. This review frames what we
have recently learned regarding how the current scope of
therapeutics for gout and hyperuricemia can be employed
more effectively, and in particular for refractory gouty inflam-
mation and hyperuricemia, focusing on new urate-lowering
drugs (febuxostat and uricases) and biologic approaches to
gouty inflammation via IL-1 inhibition.
Gout therapy: how the current armamentarium
is actually employed in the ‘real world’
Table 2 summarizes recent assessment of the scope of
application of existing therapies for gout in the USA [4], and
also highlights that primary care practitioners are, by far,
prescribing the most gout therapies. Given that there are
currently estimated to be at least approximately 3 million
people with active gout, and 3 to 6 million subjects with a
history of gout in the USA [5], the numbers summarized in
Table 1 suggest that many gout patients receive inadequate
therapy. In this context, there appears to be a shortfall in
meeting practice guidelines [6,7] for prescribing of
prophylactic colchicine relative to the allopurinol prescription
numbers. Overall, the estimated colchicine utilization rate was
only 4.6% in office visits for those with gout, versus 8.9% for
prednisone and 18% for NSAIDs [4]. As it is elsewhere in the
world, allopurinol is the first line choice for serum urate-
lowering in the great majority of subjects in the USA.
However, there appear to be large differences in prescribing
patterns for allopurinol in Caucasians relative to both African-
Americans and Asians, suggesting under-treatment of gout in
the latter two subgroups.
Advances in treatment of gouty arthritis by
better use of the current drug armamentarium
Acute gouty arthritis is mediated by the capacity of mono-
sodium urate crystals to activate multiple pro-inflammatory
Review
Gout
Novel therapies for treatment of gout and hyperuricemia
Robert Terkeltaub
Rheumatology Section, San Diego Veterans Affairs Medical Center, and University of California San Diego School of Medicine, VA Medical Center,
3350 La Jolla Village Drive, San Diego, CA 92161, USA
Corresponding author: Robert Terkeltaub, rterkeltaub@ucsd.edu
Published: 23 July 2009 Arthritis Research & Therapy 2009, 11:236 (doi:10.1186/ar2738)
This article is online at http://arthritis-research.com/content/11/4/236
© 2009 BioMed Central Ltd
ABCG2 = ATP-binding cassette sub-family G member 2; CKD = chronic kidney disease; EULAR = European League Against Rheumatism; FDA =
Food and Drug Administration; GLUT = glucose transporter; IL = interleukin; NSAID = nonsteroidal anti-inflammatory drug; PEG = polyethylene
glycol; URAT, urate transporter.Arthritis Research & Therapy    Vol 11 No 4 Terkeltaub
Page 2 of 11
(page number not for citation purposes)
pathways in the joint, culminating in early activation of
resident macrophages, and neutrophil adhesion, migration
into the joint, and activation in the synovium and joint space
that drive gouty inflammation [8,9]. Current primary options
for anti-inflammatory management of acute gout (nonsteroidal
anti-inflammatory drugs (NSAIDs), corticosteroids, and
colchicine) bluntly dampen these inflammatory mechanisms in
a cost-effective manner, though are limited by broad drug
toxicities, particularly in subjects with significant co-morbidities
[8-13]. Moreover, the evidence basis for some of these
treatments has been limited by inadequate assessment in
randomized, controlled, double-blind clinical trials, an issue
due to the intrinsic self-limitation of the acute gout flare.
The recent definition of etoricoxib as an effective COX-2-
selective inhibitor in acute gout [14] has opened up a new
therapeutic approach, but the cardiovascular safety of COX2
inhibitors remains under review. The establishment, in the
past 2 years, of the evidence basis for oral glucocortico-
steroid treatment of acute gout is also particularly significant,
for example, for subjects with CKD. Specifically, prednisolone
35 mg daily for 5 days and naproxen 500 mg twice daily for
5 days have been demonstrated to be comparable in efficacy
and tolerance in a recent trial of acute gout treatment [11].
Prednisolone (6 doses of 30 mg over 5 days) was also
comparable in efficacy to indomethacin and better tolerated
in an acute gout trial [12].
Table 1
Common features of ‘treatment-refractory’ gout that complicate management
Polyarticular gout, uncontrolled flare activity, and/or chronic synovitis
Destructive tophi
Advanced age
Co-morbidities (for example, chronic kidney disease, cardiovascular disease, obesity, metabolic syndrome or diabetes, alcohol abuse)
Polypharmacy and drug interactions (for example, statins, macrolide antibiotics, oral anticoagulants)
Contra-indications or refractoriness to NSAIDs, colchicines, and/or glucocorticosteroids
Allopurinol intolerance or hypersensitivity and inability to employ uricosurics 
Failure to adequately lower serum urate on appropriate doses of urate-lowering drugs
NSAID, nonsteroidal anti-inflammatory drug.
Table 2
Overview of recent  treatment patterns of gout in the USA
Total ambulatory visits, and visits to primary care versus specialists 
Total number of ambulatory care visits  973 million
Number of visits for gout 3.9 million (0.4% of total)
Percentage of total visits for gout to:
Primary care 69%
Cardiologists 10%
‘Other specialists or unknown’ <16%
Rheumatologists <2%
Number of gout patient-specific anti-inflammatory prescriptions (absolute number of prescriptions/year)
Colchicine  ~381,000
NSAIDs  ~700,000
Prednisone  ~341,000
Number of gout patient-specific urate-lowering prescriptions (absolute number of prescriptions/year)
Allopurinol 2.8 million
Probenecid 8,000
Demographics of allopurinol prescribing: percentage of gout patients that are:
Caucasian 80%
African Americans  49%
Asians  19%
Data from the 2002 calendar year extracted from the work of Krishnan et al. [4]. NSAID, nonsteroidal anti-inflammatory drug.Dosing guidelines and the evidence basis for colchicine in
acute gout treatment have also advanced in the past few
years. In older oral colchicine regimens where the drug was
given every 1 to 2 hours repeatedly for multiple doses, gastro-
intestinal toxicity, including severe diarrhea, was limiting, and
occurred before a 50% reduction in pain was achieved in
most subjects [13]. Intense colchicine regimens have
justifiably fallen out of favor. As an example, European League
Against Rheumatism (EULAR) expert consensus guidelines
for oral colchicine in acute gout are for a maximum of three
colchicine 0.5 mg tablets per 24 hour period [6]. Further-
more, in a large, randomized, controlled multicenter trial
comparing low dose and extended dose colchicine regimens,
results strongly supported the lower dose colchicine regimen
for acute gout [15]. In this study, within 12 hours of onset of
acute gout symptoms patients self-administered ‘high dose’
colchicine (1.2 mg followed by 0.6 mg every hour for 6 hours
(4.8 mg total)) or ‘low dose’ colchicine (1.2 mg followed by
0.6 mg in 1 hour (1.8 mg total)), or placebo. The ‘low dose’
colchicine was comparable to ‘high dose’ colchicine in
efficacy, but did not differ from placebo with respect to
diarrhea or other gastrointestinal side effects.
Advanced anti-inflammatory therapies for gout
The typical response of acute gout to NSAIDs and COX2
selective inhibition therapy, systemic glucorticosteroids, and
colchicine is rapid but incomplete (for example, approximately
50% pain reduction achieved within 2 to 3 days [11,12,14,15]).
This has left substantial room for improvement, particularly
since a potent alternative, intravenous colchicine, was
justifiably withdrawn from active marketing in the USA in
2008 due to serious safety considerations. Among selective
targets or strategies for advanced anti-inflammatories for
gouty inflammation identified in recent years are the
complement C5b-9 membrane attack complex, agonism of
phagocyte melanocortin receptor 3 (shown to be a direct
peripheral target of adrenocorticotropic hormone), the
chemokines CXC1 and CXCL8, tumor necrosis factor-α, and
the NLRP3 (NLR family, pyrin domain containing 3) inflamma-
some (Figure 1), which, via caspase-1 activation, drives IL-1β
endoproteolysis and consequent IL-1β maturation and
secretion [8,9].
Though anecdotal reports have suggested tumor necrosis
factor-α antagonism to be beneficial in some cases of
refractory human gouty inflammation [16], IL-1β appears to
be far more central than tumor necrosis factor-α in experi-
mental urate crystal-induced inflammation in mice [17].
Concordantly, the most investigated biologic drug strategy in
humans for gouty inflammation has been neutralization of IL-1,
with promising results [9,17]. A pilot study of ten patients
with chronic refractory gouty inflammation given the soluble
IL-1 receptor antagonist anakinra (100 mg daily subcutaneously
for 3 days) suggested good overall responses [17], though
results of larger, randomized, controlled studies of IL-1
inhibition for gouty arthritis are awaited.
Options in the treatment of hyperuricemia:
recent establishment of the evidence basis
for <6 mg/dL as the serum urate target level
in gout
Pharmacologic urate-lowering approaches can employ
primary, potent uricosurics (probenecid or benzbromarone),
xanthine oxidase inhibitors to inhibit uric acid generation
(allopurinol and the recently approved drug febuxostat), or
experimental uricase treatment (with Rasburicase™ or
pegloticase) to degrade urate [1,10]. Since the solubility of
urate in physiologic solutions is exceeded at approximately
6.7 to 7.0 mg/dL, current guidelines for inhibiting ongoing
urate crystal deposition, reduction of total body urate stores,
and resolution of macroscopic tophi are for continuing
(lifelong) reduction of serum urate concentration to <6 mg/dL
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Figure 1
The NLRP3 inflammasome and IL-1β processing and secretion in
crystal-induced inflammation. The figure shows monosodium urate
crystal interaction with phagocytes, with crystal recognition at the
macrophage surface mediated by innate immune mechanisms, in part
employing Toll-like receptor (TLR)2 and TLR4 and associated MyD88
signaling, Fc receptors, and integrins. Crystal uptake with consequent
phagolysosome destabilization, and reactive oxygen species
generation and lowering of cytosolic K+ all appear to promote
activation of the NLRP3 (cryopyrin) inflammasome. Consequent
endoproteolytic activation of caspase-1, which drives pro-IL-1β
maturation, and consequent secretion of mature IL-1β is a major
mechanism stimulating experimental gouty inflammation, and appears
to be implicated in human gouty arthritis, as discussed in the text.(approximately 360 mmol/l), and ideally in the 5 to 6 mg/dL
range [18]. As summarized in a detailed, recent review [18],
achieving this target level in gout patients ultimately is
associated with fewer gout flares, and it also may have direct
and indirect beneficial effects on renal function [19,20]. A
more aggressive serum urate-lowering target such as 3 to
5 mg/dL appears appropriate for more rapid tophus de-
bulking in those tophaceous gout patients with a body
burden of urate assessed to be particularly large [21].
Advances in understanding renal urate
handling and uricosuric therapy
Uricosurics act primarily by inhibiting proximal renal tubule
epithelial cell reabsorption of urate anion, thereby enhancing
renal uric acid excretion. This remains a compelling approach
in some aspects, since reduction of miscible total body urate
stores is initiated rapidly, and the velocity of tophus size
reduction is comparable to that using allopurinol when similar
degrees of serum reduction are achieved [22]. Moreover,
uricosurics target the underlying basis for hyperuricemia in
the majority of patients. Recent advances in understanding
renal disposition of urate include identification of the anion
exchanger URAT1 (urate transporter 1; SLC22A12) as a
mediator of urate anion reabsorption from the lumen at the
apical membrane of the proximal tubule epithelial cell [23],
with the electrogenic hexose transporter GLUT9 (glucose
transporter 9; SLC2A9) mediating urate anion reabsorption
into the peritubular interstitium (and ultimately into the
circulation) at the basolateral membrane [24-28]. Probenecid
and benzbromarone both inhibit urate anion movement
transduced by URAT1 and GLUT9 [24] (Figure 2). The
findings related to GLUT9 also raise compelling questions
about the relationships between hyperglycemia and increased
fructose intake and hyperuricemia [24-29].
A major advance that also could point to new and potentially
genomics-customized uricosuric strategies is the identifica-
tion of ATP-binding cassette sub-family G member 2 (ABCG2)
as one of the functional urate anion secretory transporters at
the apical membrane of the renal proximal tubule epithelial
cell (Figure 2) [30]. Moreover, genome-wide association
studies have linked common URAT1, GLUT9, and now
ABCG2 haplotypes or single nucleotide polymorphisms with
altered susceptibility to gout [23-28,30]. For example, the
common ABCG2 rs2231142 single nucleotide polymor-
phism encoding the Q141K mutation in the nucleotide-
binding domain of ABCG2 suppresses ABCG2 urate
transport rates by approximately 50% in vitro, and in a large,
population-based study, rs2231142 was strongly associated
with serum urate levels in whites, who have a minor allele
frequency of 0.11 [30]. The adjusted odds ratio for gout of
1.68 per risk allele in whites and blacks argues that
approximately 10% of all gout cases in whites may be
attributable to ABCG2 rs2231142, and the risk allele also is
highly prevalent in Asians, who have a higher gout prevalence
than whites [30].
Significantly, in current clinical practice, the most available
primary uricosuric, probenecid, requires more than once daily
dosing and increases the risk of urolithiasis, particularly in
acid urine [31]. More selective and potent uricosurics ideally
would have a once daily dosing profile and could be
designed such that urolithiasis risk is not unduly elevated. All
uricosurics also become less effective and ultimately in-
effective with progressively lower glomerular filtration rate
[10,31]. This may limit the role of combining uricosurics with
xanthine oxidase inhibition in the treatment of refractory
hyperuricemia in gout patients since xanthine oxidase
inhibition lowers urinary uric acid clearance by excretion.
Such a combination approach can normalize serum urate in a
substantial fraction of patients on submaximal allopurinol [32].
An approach of this nature, using certain drugs with wider
availability than benzbromarone (for example, losartan, and
fenofibrate) [33,34] but with less potent uricosuric action
than primary uricosurics such as probenecid, has to date
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Figure 2
Effects of URAT1, GLUT9, and ABCG2 on urate anion disposition by
the renal proximal tubule epithelial cell and inhibitory effects of the
uricosurics probenecid and benzbromarone on renal urate
reabsorption by inhibition of both URAT1 and GLUT9. The schematic
summarizes the effects of the uricosurics probenecid and
benezbromarone on urate handling in the renal proximal tubule
epithelial cell by the URAT1 (SLC22A12) and GLUT9 (SLC2A9)
transporters identified as linked with serum urate levels and gout
susceptibility in genetic studies, including recent genome-wide
association studies. Urate reabsorption at the apical membrane, which
interfaces with the tubule lumen, is mediated in large part by the anion
exchange function of URAT1. At the basolateral membrane, the hexose
transport facilitator GLUT9 electrogenically transports urate anion into
the peritubular interstitium, where urate is reabsorbed into the
circulation. Recent genome-wide association studies and functional
genomics analyses have also uncovered a substantial role for ABCG2
in secretion of urate into the proximal tubule lumen. The depicted
model is a simplification, since other molecules that affect urate
disposition in the proximal tubule and distally in the nephron are not
depicted here, and effects of certain other drugs on renal urate
disposition by inhibiting URAT1 or GLUT9 or other transporters are not
represented. ABCG, ATP binding cassette sub-family G; GLUT,
glucose transporter; URAT1, urate transporter 1.been, at best, only moderately successful, when studied in
only small numbers of subjects, as a potential strategy to
further lower serum urate where there is suboptimal control
with allopurinol. It appears likely that such combination
strategies will be particularly constrained in effectiveness in
those with stage 3 CKD or worse (creatinine clearance <60
calculated by Cockroft-Gault equation and adjusted for ideal
body weight).
Advances in understanding allopurinol
treatment failure
Given the limitations of uricosuric therapy highlighted above,
the first line of pharmacologic therapy to lower serum urate
for most gout patients is suppression of xanthine oxidase
using allopurinol, which, when effective and well-tolerated, is
a cost-effective option [6,10]. Allopurinol is US Food and
Drug Administration (FDA) approved for doses up to 800 mg
daily [35]. Recent expert consensus EULAR guidelines have
reinforced FDA dosing guidelines for allopurinol in patients
with preserved renal function [6,35], specifically to initiate
allopurinol at 100 mg daily, and then to increase the dose by
100 mg every 1 to 4 weeks until a target serum urate level
(<6 mg/dL) is achieved or the maximum appropriate allo-
purinol dose is reached. FDA dosing guidelines have also
advocated 200 to 300 mg allopurinol daily as adequate for
most patients with mild gout, and an average dose of 400 to
600 mg allopurinol daily as the expected amount to control
hyperuricemia in patients with moderately severe tophaceous
gout [35]. In small studies of gout patients, the mean daily
dose of allopurinol needed to normalize serum urate was
372 mg [36], and allopurinol dose increases from 300 mg to
600 mg daily markedly increased serum urate-lowering effici-
ency in patients without stage 3 or worse CKD [37]. Data
from recent, large, randomized, controlled clinical trials
indicated that allopurinol 300 mg daily lowered serum urate
by approximately 33% in a population of gout patients where
approximately 25 to 30% had detectable tophi, serum urate
was approximately 9.5 to 10 mg/dL, and renal function was
largely intact [38,39].
In clinical practice, noncompliance with allopurinol has
recently been elucidated to be a problem in approximately
50% of subjects in the first year of therapy [40]. Moreover, it
appears that allopurinol is widely under-dosed overall in
clinical practice, since the vast majority of allopurinol
prescriptions are for 300 mg daily or less [41]. This circum-
stance reflects influential maintenance dosing guidelines for
allopurinol in CKD dating from the 1980s and calibrated for
serum levels (in relationship to estimated glomerular filtration
rate) of oxypurinol, which is the major, long-lived active
allopurinol metabolite and is primarily excreted by the kidney
[35]. The intent of the older guidelines was to lessen the
incidence of allopurinol hypersensitivity syndrome, particularly
with CKD [35]. These guidelines are now recognized not to
be based on evidence, to fail to adequately treat hyper-
uricemia, and also to fail to prevent allopurinol hypersensitivity
syndrome in all patients, including those with CKD [35,42].
Though HLA-B58 is a newly identified risk factor for severe
cutaneous adverse reactions to allopurinol (that is, Stevens-
Johnson syndrome or toxic epidermal necrolysis) [43-45],
there remains no reliable way to identify whether an individual
patient will develop such toxicity on allopurinol [35,42].
FDA and more recent EULAR dosing guidelines for
allopurinol have suggested the use of reduced doses in renal
failure in order to lessen the risk of drug toxicity [6,35]. For
example, the FDA-recommended maximum allopurinol dose is
200 mg daily with a creatinine clearance of 10 to 20 ml/min,
and 100 mg daily with a creatinine clearance of <10 ml/min.
More recently, dose reduction of allopurinol in moderate CKD
was supported via retrospective analysis of renal function-
adjusted dosing of allopurinol in relation to drug toxicities
[46]. The lack of a definition of safety and tolerability of
allopurinol maintenance doses above those previously
calibrated for serum oxypurinol levels related to creatinine
clearance [46] needs to be considered when weighing the
decision to employ more advanced serum urate lowering
therapeutic options.
Advanced options for treatment-refractory
hyperuricemia in gout: febuxostat
The xanthine oxidase inhibitor febuxostat, now approved in
Europe and the USA, is an appropriate choice in circum-
stances of allopurinol hypersensitivity or intolerance, or failure
of allopurinol (at a maximal dose appropriate for the individual
patient) to normalize serum urate and, ultimately, improve
physical function and quality of life parameters. Febuxostat is
a particularly appropriate second line option to allopurinol
where uricosuric therapy is contra-indicated, as in stage 3 or
worse CKD, and in patients with a history of urolithiasis, an
inability to adequately increase hydration, or with identified
uric acid overproduction [21].
Febuxostat is a selective inhibitor of xanthine oxidase, the
drug sitting in the access channel to the molybdenum-pterin
active site of the enzyme [47]. Febuxostat does not have a
purine-like backbone, unlike allopurinol and oxypurinol
(Figure 3). Significantly, febuxostat is primarily metabolized by
oxidation and glucuronidation in the liver and renal elimination
plays a minor role in febuxostat pharmacokinetics, as
opposed to allopurinol pharmacology. Febuxostat also does
not directly regulate pyrimidine metabolism and it is not
reincorporated into nucleotides, in contrast to allopurinol,
where such properties have the potential to contribute to
certain drug toxicities.
Febuxostat 40 to 120 mg daily (and a safety dose trial of
240 mg daily) has now been analyzed in large, randomized,
clinical trials in which tophi were seen in approximately 25 to
30% of subjects, with a maximum dose of 300 mg allopurinol
employed in comparison groups [38,39,48,49]. Results of all
of these trials unequivocally established the failure of 300 mg
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<6 mg/dL in a substantial majority of the patient population
studied. In a 52-week trial, febuxostat 80 and 120 mg both
achieved the target level of serum urate <6 mg/dL in the
majority of subjects, though gout flare rates at 52 weeks were
comparable to those in subjects randomized to allopurinol
300 mg daily [38]. In a second, large phase 3 trial, febuxostat
40 mg daily demonstrated serum urate-lowering to target of
<6 mg/dL roughly equivalent to allopurinol 300 mg daily in
those with intact renal function, and 80 mg febuxostat daily
was superior to allopurinol 300 mg or febuxostat 40 mg daily
in achieving a serum urate target level of <6 mg/dL, with
comparable drug tolerance [48]. In a subset of patients with
stage 2 to 3 CKD, febuxostat 40 and 80 mg daily were also
superior in achieving the serum urate target level in
comparison to renally dose-adjusted allopurinol (200 to
300 mg daily) [48].
Comparison of early gouty arthritis flares, triggered by serum
urate-lowering and putative remodeling, was instructive in
these studies. The early flares occurred in association with
the most intense serum urate-lowering effect in both
febuxostat and allopurinol recipients, and early flares were a
greater problem when prophylactic colchicine was stopped
at 8 weeks as opposed to 6 months into urate-lowering
treatment, but gout flares tapered off later in this study
[38,48]. For these reasons, the European Medicines Agency
(EMEA) astutely recommended gout flare prophylaxis for a
6 month period when febuxostat is initiated.
Tophus size is reduced by 50 to 80% after 1 year of either
febuxostat or allopurinol treatment, with the greatest tophus
and gout flare reduction linked to the greatest degree of
serum urate-lowering irrespective of drug. A small, open-label
extension study in which patients failing initial therapy on
allopurinol were switched to febuxostat to achieve serum
urate <6 mg/dL suggested that approximately half of
febuxostat-treated patients with tophi can achieve elimination
of tophi by 2 years, and approximately 70% by 5 years [49].
Quality of life parameters have been favorably impacted by
extended febuxostat treatment in uncontrolled studies [49].
Febuxostat is approved for use in European countries at 80
and 120 mg daily. The FDA approved febuxostat for use in the
USA in February, 2009. The USA label is for a dose of 40 mg
daily, followed by dose increase to 80 mg daily if serum urate
is not normalized after at least 2 weeks. Side effects of
febuxostat include rash in <2% of subjects, and elevation of
hepatic enzymes, diarrhea, and arthralgia may also occur. As is
the case for allopurinol, xanthine oxidase inhibition by
febuxostat carries the potential for major drug interactions with
azathioprine, 6-mercaptopurine and theophylline [50].
Uricase therapy: an experimental ‘biologic’
option for serum urate lowering
Uricases oxidatively degrade uric acid, thereby catalyzing
conversion to soluble allantoin, which is much more soluble
than uric acid [51]. Uricases also generate 1 mole of the
oxidant hydrogen peroxide for each mole of uric acid
degraded (Figure 4). Uricase expression was lost in humans
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Figure 3
Comparison of allopurinol, oxypurinol, and febuxostat structures.
Allopurinol and its long-lived major active metabolite oxypurinol (both
pictured) inhibit xanthine oxidase, as does febuxostat (pictured), which,
in contrast to the other two agents, does not have a purine-like
backbone.
Figure 4
Enzymatic activity of uricase (uric acid oxidase). Uricase oxidizes uric
acid, which is sparingly soluble, to the highly soluble end product
allantoin, which is readily excreted in the urine. In doing so, uricase
generates not only intermediate forms of uric acid that are subject to
further metabolism (including 5-hydroxyisourate), but also the oxidant
hydrogen peroxide as a byproduct of the enzymatic reaction. During
evolution, humans and higher primates lost expression of not only
uricase, but also enzymes that rapidly degrade intermediate forms of
uric acid generated by uric acid oxidation.and higher primates during the course of evolution [1].
Illustrating the huge role uricase plays in uric acid homeo-
stasis in mammals, normal serum urate in rodents is approxi-
mately 1 mg/dL, whereas it is approximately 10 mg/dL in
uricase knockout mice. Moreover, untreated hyperuricemia in
uricase knockout mice leads to death by renal failure due to
severe uric acid urolithiasis.
Various uricase therapies for hyperuricemia have been
attempted experimentally for several decades [52]. For
example, recent, limited reports or pilot studies have
evaluated the off-label use in severe, chronic gout of the non-
PEGylated recombinant fungal enzyme rasburicase [52,53],
which is FDA-approved for single course therapy in pediatric
tumor lysis syndrome. Unfortunately, rasburicase is both
highly antigenic and has a plasma half-life of 18 to 24 hours
[52]. Efficacy, tolerability, and sustainability of rasburicase
treatment beyond 6 to 12 months appear to be poor for
treatment of refractory hyperuricemia in gout [52,53].
A recent advance has been seen in clinical trials of
recombinant porcine-baboon uricase (pegloticase); these
trials have evaluated the potential advantages for sustained
management of refractory hyperuricemia in gout of PEGylation
of this enzyme (Figure 5) to reduce immunogenicity as well as
increase circulating half-life [51,54,55]. For refractory
tophaceous disease, results to date indicate that intravenous
PEGylated uricase treatment has the potential to rapidly
decrease the pool size of miscible urate, and also to de-bulk
tophi in weeks to months [56] rather than the months to years
seen to date with therapy with xanthine oxidase inhibitors at
conventional doses. Specifically, in a phase 2 and a pivotal
placebo-controlled, randomized, 6-month phase 3 trial with
open-label extension (approximately 40 and 200 patients,
respectively), intravenous administration of pegloticase (up to
8 mg every 2 weeks) induced profound initial reductions of
serum urate [55,57]. In the pivotal phase 3 trial of
pegloticase, which assessed a patient population with severe
gout overall (and approximately 70% with visible tophi) [57],
pre-infusion of fexofenadine, acetaminophen, and hydrocorti-
sone (200 mg) were employed in an attempt to limit infusion
reactions [57]. The frequency of responders - subjects who
reached a target serum urate level of <6 mg/dL at 6 months -
was approximately 42% on 8 mg pegloticase every 2 weeks
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Figure 5
Molecular models of the uricase tetramer and of the PEGylated uricase pegloticase containing strands of 10 kDa polyethylene glycol (PEG) linked
to each uricase tetramer. (a) Schematic model of the uricase tetramer, based on the crystal structure of Aspergillus flavus uricase. Each subunit is
shown in a different color (red, blue, green, or yellow). (b) Space-filling model of the A. flavus uricase tetramer, showing the characteristic tunnel
(or barrel) structure of the native enzyme tetramer. (c) Space-filling model of A. flavus uricase tetramer, rotated around the vertical axis so that the
tunnel is not visible. (d) Space-filling model of the uricase tetramer in the same orientation as in (b) but to which nine strands of 10 kDa PEG per
uricase subunit are attached. The structures of the PEG strands (shown in various shades of gray) were generated as described in [54]. The scale
of (d) is about half that of (a-c). Figure 5 and the legend are reprinted with permission from [54].in the intent to treat analysis [57]. Moreover, de-bulking of
tophi in this study was notably rapid in the subset of patients
on pegloticase 8 mg every 2 weeks, with complete resolution
of tophi in 20% by 13 weeks and approximately 40% by
25 weeks [56].
Frequent early acute gout flares (up to approximately 80%) in
the first few months of pegloticase therapy [55] tapered off
with more prolonged therapy in responders. Infusion reac-
tions were moderate to severe in approximately 8 to 11% of
subjects, and included flushing, urticaria, and hypotension,
and, by undefined mechanisms, noncardiac chest pain or
muscle cramping [55,57]. Anaphylaxis was uncommon
(approximately 2%) in the phase 3 pegloticase study [57].
However, high titer antibodies to pegloticase emerged in
many patients as treatment evolved over a few months,
including IgM and IgG antibodies that did not directly neutra-
lize the enzyme but appeared to adversely alter both its
pharmacokinetics and pharmacodynamics [58]. High titer
anti-pegloticase antibodies were also strongly linked with
infusion reactions and were rare in serum urate responders
(as assessed at the 6-month time-point) [58]. Hence, the
dense polyethylene glycol (PEG) multimers linked to peglo-
ticase [54] (Figure 5) do not prevent antigenicity, and also
have been suggested to independently modulate the immune
response to pegloticase in some subjects[58].
All uricase therapies have the potential to induce oxidative
stress, since degradation of the high micromolar plasma
concentrations of urate in gout patients by uricases has the
capacity to generate substantial amounts of hydrogen
peroxide [1,59,60]. Whether increased nitric oxide bioavaila-
bility [61,62] and the profound, rapid decrement in the serum
antioxidant activity normally exerted by serum urate [1] contri-
bute to oxidative challenge by uricase therapy is not yet clear.
Circulating oxidative stress triggered by hydrogen peroxide
generation alone is subject to marked dampening by the
normal abundance of catalase on erythrocytes [51,59,60]
and potentially by other plasma antioxidant defenses. Yet
methemoglobinemia and/or hemolysis have been unequivocal
indicators of uricase-induced oxidative stress [1,59,60].
Importantly, with Rasburicase™ therapy, methemoglobinemia
and hemolysis (fortunately <1% in incidence) were linked to
glucose-6-phosphate dehydrogenase deficiency in some but
not all affected subjects [59,60]; subsequently, this deficiency
has become an exclusion criterion for any uricase therapy. It
has been suggested that assessment for erythrocyte catalase
activity should be done prior to uricase therapy [59,60]. In my
opinion, monitoring for treatment-induced subclinical met-
hemoglobinemia also could ultimately be informative.
Uricases, by oxidizing urate (Figure 4), generate the inter-
mediate form 5-hydroxyisourate, and subsequent hydrolysis
of this produces 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazo-
line, which is decarboxylated to S-(+)-allantoin [63]. The
enzymes carrying out rapid degradation of these urate
oxidation intermediates were lost in human evolution along
with uricase [63]. It has been suggested that addition of
these enzymes to uricase therapy would be useful if the
aforementioned uric acid oxidation intermediates are found to
have noxious biologic properties [63].
Overall, it is not yet known if there is significant subclinical
oxidative stress at the tissue level, rather than simply at the
erythrocyte level [59,60], with uricase treatment in gout
patients. Because of this issue, close monitoring of uricase-
treated gout patients appears in order. Whether potential
concomitant oxidative stress due to selected co-medications,
congestive heart failure, anemia, hyperlipidemia, and CKD
influences uricase safety remains to be defined.
At the time of writing this review, uricase therapy for
tophaceous gout for which treatment has failed remains an
unapproved, experimental approach that will be substantially
more expensive than oral therapies, and consensus,
evidence-based therapeutic guidelines are needed, whereas
only draft guidelines have been proposed for uricase [52].
Tophus debulking is impressively rapid (months) in res-
ponders, but uricase therapies tested to date have all been
substantially limited by drug immunogenicity. The safety of
this particular ‘biologic’ approach, especially beyond a term
of 6 to 12 months, will require further investigation.
In my opinion, any form of uricase therapy (over a finite term)
is appropriate only for carefully selected patients that would
benefit from accelerated, tophus de-bulking to address
incapacitating tophi linked with active synovitis, and where
other serum urate lowering therapies have failed or cannot
achieve this objective [52]. As an ‘induction therapy’, uricase
could ultimately be replaced by less intensive maintenance
oral urate-lowering therapy with other agents, once evidence
of normalization of body urate stores, including resolution of
clinically detectable tophi and gross synovitis, is achieved.
Do cardiovascular safety signals in
urate-lowering trials in gout reflect the
influence of inflammation?
There have been death signals in both congestive heart
failure patients on experimental oxypurinol therapy [64] and
febuxostat-treated gout patients [48]. Moreover, there is
higher cardiovascular mortality in hyperuricemia gout patients,
related in part to co-morbidities in gout, and also possibly to
independent effects of hyperuricemia on the vasculature
[65,66].
Clinical trials to date in which death signals have arisen with
serum urate-lowering strategies all have limitations in
interpretability due to small numbers of events and subjects
and relatively short durations of treatment. Hence, statistical
significance may not be in lockstep with clinical and
biological significance in such studies to this point. One
constant associated with the more intense serum urate
Arthritis Research & Therapy    Vol 11 No 4 Terkeltaub
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uricemics is increased risk for acute gout flares in the first few
months of therapy [38,55]. In my opinion, the known asso-
ciation of atrial and ventricular arrythmias and quantifiable
altered heart rate variability with systemic inflammation
(putatively mediated by specific cytokines markedly up-
regulated in acute gouty inflammation, such as IL-6 and
CXCL8) [67-69] deserves direct investigation as a potential
factor in cardiovascular morbidity and mortality in gout
patients undergoing serum-urate lowering therapy.
Challenges in translating novel gout and
hyperuricemia therapies to better clinical
practice
Compliance of gout patients with therapy appears lower than
that for therapy of a variety of other common medical
conditions, including hypertension, diabetes, osteoporosis,
and hyperlipidemia [70]. Younger gout patients with fewer
co-morbidities and fewer office visits are the least compliant
gout patients, and we need to address systematic failures in
both physician and patient education in gout treatment.
Physicians appear to underestimate the impact of gout on
quality of life and physical function [71-74]. Gout patients
have more co-morbidities, poorer quality of life and physical
function, increased health care costs, and increased adverse
cardiovascular outcomes than controls [65,71-75].
Not only patient education, but also quality of care in gout
treatment have significant room for improvement [76-78]. The
identification of certain improved outcomes with sustained
serum urate lowering below 6 mg/dL has ushered in a new
era of gout therapy, where practitioners ‘treat to target’ in
lowering serum urate [18]. Now the true definition of
‘treatment-refractory’ gout and gout-specific quality of life and
disability will need careful assessment and direct attention in
clinical practice. Such efforts would be timely, since
‘treatment-refractory’ gout, associated with an overall
decrease in quality of life [79], has been proposed as a
specific indication for aggressive urate-lowering strategies
and possibly for initially lower serum urate targets than the
widely used metric of <6 mg/dL [21].
The future of gout treatment is intriguing. For example,
promising genomics and imaging technologies have the
potential to improve prevention, diagnosis, and therapy by
identifying disease earlier and tailoring treatment strategies.
Examples include single nucleotide polymorphism and
haplotype identification for renal urate transporters in patients
with hyperuricemia [80]. Dual energy computed tomography,
which is highly sensitive and specific in visualizing tissue
stores of monosodium urate crystals as well as renal uric acid
urolithiasis [81,82], has the potential, for example, to assist in
diagnosis of gout in patients with hyperuricemia or joint pain,
and to better quantify tophus dissolution in therapy.
Whether using well-established or newer and emerging
approaches and agents for gout and hyperuricemia manage-
ment, the bottom line will remain that gout and hyperuricemia
treatments need to be better translated into a collective of
favorable outcomes for both control of gouty inflammation
and management of hyperuricemia, as well as improved
outcomes of gout-related quality of life and co-morbidities.
This will require careful attention to both drug safety and
cost-effectiveness of established versus emerging therapies,
relative to quantifiable patient-centered outcomes, in a
financially challenging era.
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